Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
50%(2 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_2
3
50%
Ph not_applicable
1
17%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
3(50.0%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(2)

Detailed Status

Completed4
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (33.3%)
Phase 23 (50.0%)
N/A1 (16.7%)

Trials by Status

completed467%
terminated233%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_2

Study of Immune Response Modifier in the Treatment of Hematologic Malignancies

NCT00276159
completedphase_2

Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers

NCT00319748
completedphase_1

Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors

NCT00095160
terminatednot_applicable

Pilot Study of Oral 852A for Elimination of High-Grade Dysplasia in Barrett's Esophagus

NCT00386594
completedphase_1

Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions

NCT00091689
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00276159Phase 2

Study of Immune Response Modifier in the Treatment of Hematologic Malignancies

Terminated
NCT00319748Phase 2

Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers

Completed
NCT00095160Phase 1

Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors

Completed
NCT00386594Not Applicable

Pilot Study of Oral 852A for Elimination of High-Grade Dysplasia in Barrett's Esophagus

Terminated
NCT00091689Phase 1

Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions

Completed
NCT00189332Phase 2

Use of 852A in Metastatic Cutaneous Melanoma.

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6